INNODIA communication on conduct of clinical trials in the context of the Covid-19 pandemic
19. March 2021
Within INNODIA and INNODIA HARVEST projects we are running a number of early phase clinical intervention trials with the aim to arrest the progression of the beta-cell destruction from diagnosis in Type 1 diabetes. However, in 2021 we are still confronted with the COVID-19 pandemic that has some impact on our trial activities.
Our priority is to keep everyone safe and free of infection whilst encouraging the roll-out of COVID-19 vaccination as it becomes available to our target population.
The agents we are testing in the trials vary considerably in terms of their potential influence upon SARS-CoV-2 infection and their potential to affect the development of full immunity after COVID-19 vaccination. For these reasons, each individual trial is providing specific guidance on screening for SARS-CoV-2 and on vaccination against COVID-19.
Please get in touch with respective study teams if you have any questions or concerns.